Taiho
As of the edition of 20 October 2026, Taiho runs 45 drugs, 17 of them marketed; it is on route A at 18 targets and on route B at 12 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 17 |
| Active | 8 |
| Went quiet | 2 |
| Stopped | 15 |
| Status not established | 3 |
| Total | 45 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Tegafur | none listed | 2 |
| Palonosetron | none listed | 3 |
| Trifluridine | none listed | 0 |
| Tipiracil | Ends 2034 (patent) | 1 |
| Tazobactam | none listed | 0 |
| Trabectedin | none listed | 0 |
| Cedazuridine | Ends 2034 (patent) | 1 |
| Piperacillin | none listed | 0 |
| Gimeracil | none listed | 2 |
| Oteracil | none listed | 2 |
| Futibatinib | Ends 2036 (patent) | 4 |
| Bilastine | none listed | 2 |
| Propiverine | none listed | 0 |
| Lafutidine | none listed | 1 |
| TAS-116 | none listed | 2 |
| Fosnetupitant | Ends 2032 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 18 targets, route B at 12 targets.
All 30 rows on route A or B
In the product30 company-target rows on route A or B; 27 are not shown here, and no score is.
See all 30 targets where Taiho needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 44 trials led
- Digestive system: 16 trials led
- Blood and lymph: 9 trials led